Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorUniversity of North Carolina, Chapel Hill

About this trial

The overall short-term goals of this project include the following: 1) identify the genes that are key to the function of respiratory cilia to protect the normal lung; and 2) the effects of genetic mutations that adversely affect ciliary function and cause primary ciliary dyskinesia (PCD), which results in life-shortening lung disease. The long-term goal of this project is to develop better understanding of the underlying genetic variability that adversely modifies ciliary function, and predisposes to common airway diseases, such as asthma and chronic obstructive pulmonary disease.

Eligibility criteria

Qualifiers

Patients who have a high suspicion for the diagnosis of PCD, based on clinical features

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

1,800 Participants
are grouped into 1 trial group

Sponsors and collaborators

University of North Carolina, Chapel Hill

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator